Home » Topics » Disease categories and therapies » Cardiovascular

Cardiovascular
RSS

Alpha1-antichymotrypsin analogues described in patent literature

Oct. 17, 1997

Do calcium channel blockers increase risk of cancer?

Oct. 16, 1997

Takeda's Blopress approved in EC

Oct. 16, 1997

Novel squalene synthase inhibitor reported by Pfizer

Oct. 15, 1997

Lenercept evaluated in phase II for sepsis/septic shock; development for RA halted

Oct. 15, 1997

New agent for restenosis reported by Taiho

Oct. 15, 1997

PRIME II: another heart failure drug associated with increased mortality

Oct. 15, 1997

Cardiovascular/Renal Drugs Advisory Committee meets this month

Oct. 14, 1997

DCLHb evaluated in critically ill patients

Oct. 13, 1997

CV Therapeutics moves ranolazine to phase III

Oct. 13, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...